An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT02752204 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
36
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Birmingham

Collaborators